Head-to-head · WeighScore
CoreAge Rx vs WellMedr
By GLP-1 ScorecardUpdated
Score comparison
CoreAge Rx has the higher recorded score — 89.5/100 to 63.2/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
CoreAge Rx scores 89.5/100 (B+).
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | CoreAge Rx | WellMedr |
|---|---|---|
| WeighScore | 89.5/100 | 63.2/100 |
| Grade | B+ | C |
| Site position | #1 | #221 |
| Semaglutide | Product page from $79/mo; navigation $99. Confirm selected quote. | Advertised from $49/month; selected upfront total, plan term and renewal amount need confirmation |
| Tirzepatide | From $129/mo advertised; confirm selected charge, supply and renewal. | Advertised from $89/month; selected upfront total, plan term and renewal amount need confirmation |
| Coverage | US only; therapy-specific state restrictions apply | General service page lists all 50 states, DC, Puerto Rico and Guam; exact medication, clinical eligibility and pharmacy fulfillment remain conditional |
| Brand-name access | Not confirmed | Yes |
| Oral / sublingual | Not confirmed | Yes |
Site position #1 · B+
Strengths
- Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
- Advertises the same price across doses and no membership fee
- Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy
What to consider
- Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
- FAQ no-rebill and payment-timing statements differ from the subscription and order policy
- FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
- Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
- Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Site position #221 · C
Strengths
- Publishes separate descriptions of 21-day billing and fully prepaid three-, six- and twelve-month plans
- The refund policy provides detailed renewal and unused-prepayment rules, although important provisions conflict with the Terms
- Current documents name possible pharmacy partners, including Logos, Emerald and Center City; the assigned facility still needs confirmation
- The safety page distinguishes compounded preparations from FDA-approved products rather than treating shared ingredients as proof of equivalence
What to consider
- Starting $49 and $89 advertisements do not establish the total due today, renewal amount or usable prescription supply; confirm whether membership and medication are separate charges
- Four-week shipping is not the billing calendar; the separately described 21-day plan can generate more frequent charges
- The refund policy accepts cancellation before a charge is submitted, while the Terms require two days’ notice and allow early renewal processing
- Unused-prepayment allocation in the refund policy conflicts with discretionary partial refunds, medication-plan cancellation windows and a nonrefundable first membership month in the Terms; no legal priority is established
- The ninety-day results-refund promise conflicts with policy language denying a results guarantee; clarify the selected written agreement
- The current directory does not establish an available oral or microdose GLP-1 purchase; the homepage labels microdose Coming soon
- Current documents do not identify the assigned clinical practice, clinician, dispenser or physical compounder; general service coverage does not guarantee every preparation
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.